Aromatase inhibitors and male breast cancer
Clin. transl. oncol. (Print)
; 9(3): 192-194, mar. 2007.
Artigo
em Inglês
| IBECS
| ID: ibc-123288
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
The majority of breast cancers in male patients are hormone receptor positive. Tamoxifen has proven to be successful in both adjuvant and metastatic settings and remains the standard of care. Given the improved outcomes in female patients with aromatase inhibitors (AI), these drugs have become a potential therapeutic tool for male patients. Preliminary data show effective suppression of oestradiol levels in males treated with AI and some reports have demonstrated objective responses. Here we report a case of a male patient with metastatic breast cancer treated with letrozole who achieved clinical response associated with a decrease in blood oestradiol levels (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Acetonitrilas
/
Progesterona
/
Triazóis
/
Carcinoma Ductal de Mama
/
Neoplasias da Mama Masculina
/
Antineoplásicos Hormonais
/
Inibidores da Aromatase
/
Estrogênios
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2007
Tipo de documento:
Artigo
Instituição/País de afiliação:
Royal Marsden Hospital/UK